#Ranbaxy launches India’s first biosimilar Infimab™ for treatment of #rheumatoid arthritis pic.twitter.com/7MQlHE27jq
— Press Release Watch (@PrReleaseWatch) December 1, 2014
Ranbaxy Laboratories has launched Biosimilar drug Infimab™ in India at the Indian Rheumatology Association Conference (IRACON) in Chandigarh.Infimab™, is being introduced in the Indian market through a licensing partnership with EPIRUS Biopharmaceuticals, Inc. a US and Swiss-based Biopharmaceutical Company. Infimab™ will be manufactured by Reliance Life Sciences at a facility in Mumbai. Infimab™ marks Ranbaxy's entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis.
Rajeev Sibal, Vice President & Country Head-India Region, Ranbaxy, said, "Infimab™ offers a new opportunity in the management of conditions like rheumatoid arthritis. The product has been developed as per global standards and delivers a similar clinical outcome to the innovator. It will be available in India at a very significant discount as compared to the innovator drug. More Indian patients will get the benefit of a world-class biologic treatment."Amit Munshi, president and CEO of EPIRUS, stated, "We are delighted to partner with Ranbaxy to bring Infimab™ to India. Infimab™ represents an affordable solution for patients and may expand patient access to this important medicine."
